Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-7.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
10.7
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
-3.7
Book Value
$-0.4
EPS
$-3
Face value
--
Shares outstanding
26,832,500
CFO
$-610.57 Mln
EBITDA
$-710.13 Mln
Net Profit
$-672.89 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syros Pharmaceuticals (SYRS)
| -90.4 | -- | -81.2 | -99.6 | -87.1 | -81.4 | -- |
|
BSE Sensex
| 5.3 | 0.4 | 9.2 | 6.6 | 17.1 | 18.9 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Syros Pharmaceuticals (SYRS)
| -97.0 | 117.0 | -89.0 | -70.0 | 57.0 | 24.1 | -42.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syros Pharmaceuticals (SYRS)
|
0.0 | 0.8 | 0.4 | -97.8 | -23,959.8 | -- | -- | 10.7 |
| 49.9 | 7,861.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.2 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.5 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.0 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.1 | |
| 40.4 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 52.8 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 309.4 | 8,699.8 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.1 | 14.7 | |
| 25.9 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 126.6 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 5.0 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in... Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Read more
Scientific Founder, Member of Scientific Advisory Board & Director
Dr. Richard A. Young Ph.D.
Scientific Founder, Member of Scientific Advisory Board & Director
Dr. Richard A. Young Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Syros Pharmaceuticals Inc (SYRS) stood at $ 113 Mln as on 30-Sep-24
The share price of Syros Pharmaceuticals Inc (SYRS) is $0.02 (NASDAQ) as of 20-Jun-2025 15:52 EDT. Syros Pharmaceuticals Inc (SYRS) has given a return of -87.08% in the last 3 years.
Syros Pharmaceuticals Inc (SYRS) has a market capitalisation of $ 1 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Syros Pharmaceuticals Inc (SYRS) is 10.65 times as on 20-Jun-2025, a 282% premium to its peers’ median range of 2.79 times.
Since, TTM earnings of Syros Pharmaceuticals Inc (SYRS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Syros Pharmaceuticals Inc (SYRS) and enter the required number of quantities and click on buy to purchase the shares of Syros Pharmaceuticals Inc (SYRS).
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
The CEO & director of Dr. Richard A. Young Ph.D.. is Syros Pharmaceuticals Inc (SYRS), and CFO & Sr. VP is Dr. Richard A. Young Ph.D..
There is no promoter pledging in Syros Pharmaceuticals Inc (SYRS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Syros Pharmaceuticals Inc. (SYRS) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-23959.84
|
|
Net Margin(%)
|
-25340.67
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Syros Pharmaceuticals Inc (SYRS) was $0 Mln.
$-0.08
(
